TP53 and fatty liver disease: Furthermore, AAV‐mediated p53 silencing did not abrogate the beneficial effects of Nutlin‐3a on hepatic steatosis, inflammation, fibrosis, and liver injury (Figure S18 and Table S6, Supporting Information).